Skip to main content

NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery.

Publication ,  Journal Article
Chetvertkov, M; Monroe, JI; Boparai, J; Solberg, TD; Pafundi, DH; Ruo, RL; Gladstone, DJ; Yin, F-F; Chetty, IJ; Benedict, S; Followill, DS ...
Published in: Front Oncol
2020

PURPOSE: To assess stereotactic radiotherapy (SRT)/stereotactic body radiotherapy (SBRT) practices by polling clinics participating in multi-institutional clinical trials. METHODS: The NRG Oncology Medical Physics Subcommittee distributed a survey consisting of 23 questions, which covered general technologies, policies, and procedures used in the Radiation Oncology field for the delivery of SRT/SBRT (9 questions), and site-specific questions for brain SRT, lung SBRT, and prostate SBRT (14 questions). Surveys were distributed to 1,996 radiotherapy institutions included on the membership rosters of the five National Clinical Trials Network (NCTN) groups. Patient setup, motion management, target localization, prescriptions, and treatment delivery technique data were reported back by 568 institutions (28%). RESULTS: 97.5% of respondents treat lung SBRT patients, 77.0% perform brain SRT, and 29.1% deliver prostate SBRT. 48.8% of clinics require a physicist present for every fraction of SBRT, 18.5% require a physicist present for the initial SBRT fraction only, and 14.9% require a physicist present for the entire first fraction, including set-up approval for all subsequent fractions. 55.3% require physician approval for all fractions, and 86.7% do not reposition without x-ray imaging. For brain SRT, most institutions (83.9%) use a planning target volume (PTV) margin of 2 mm or less. Lung SBRT PTV margins of 3 mm or more are used in 80.6% of clinics. Volumetric modulated arc therapy (VMAT) is the dominant delivery method in 62.8% of SRT treatments, 70.9% of lung SBRT, and 68.3% of prostate SBRT. CONCLUSION: This report characterizes SRT/SBRT practices in radiotherapy clinics participating in clinical trials. Data made available here allows the radiotherapy community to compare their practice with that of other clinics, determine what is achievable, and assess areas for improvement.

Duke Scholars

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2020

Volume

10

Start / End Page

602607

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chetvertkov, M., Monroe, J. I., Boparai, J., Solberg, T. D., Pafundi, D. H., Ruo, R. L., … Sohn, J. W. (2020). NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery. Front Oncol, 10, 602607. https://doi.org/10.3389/fonc.2020.602607
Chetvertkov, Mikhail, James Ira Monroe, Jaskaran Boparai, Timothy D. Solberg, Deanna H. Pafundi, Russell L. Ruo, David J. Gladstone, et al. “NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery.Front Oncol 10 (2020): 602607. https://doi.org/10.3389/fonc.2020.602607.
Chetvertkov M, Monroe JI, Boparai J, Solberg TD, Pafundi DH, Ruo RL, et al. NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery. Front Oncol. 2020;10:602607.
Chetvertkov, Mikhail, et al. “NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery.Front Oncol, vol. 10, 2020, p. 602607. Pubmed, doi:10.3389/fonc.2020.602607.
Chetvertkov M, Monroe JI, Boparai J, Solberg TD, Pafundi DH, Ruo RL, Gladstone DJ, Yin F-F, Chetty IJ, Benedict S, Followill DS, Xiao Y, Sohn JW. NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery. Front Oncol. 2020;10:602607.

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2020

Volume

10

Start / End Page

602607

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis